HealthDay - THURSDAY, May 14 (HealthDay News) -- In a phase 3 clinical trial, an experimental immune-based treatment boosted by 20 percent the overall survival of those with tough-to-treat neuroblastoma, which affects mostly children.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.